Answers are grounded in this paper and cite their sources.
A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib. These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor. Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.
No takes yet. Share an insight, caveat, or question.
Lynch et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: